

Disclaimer: This document is an English translation of the original document in Japanese and has been prepared solely for reference purposes. In the event of any discrepancy between this English translation and the original in Japanese, the original shall prevail in all respects.



November 7, 2023

To whom it may concern:

Company name	KISSEI PHARMACEUTICAL CO., LTD.
Representative	Mutsuo Kanzawa, Chairman and CEO (Stock code 4547; Prime Market, Tokyo Stock Exchange)
Contact	Takahide Kitahara, Managing Director, Department Manager of Corporate Finance and Management Department, CFO (Telephone +81-263-25-9081)

Announcement concerning the Results of the Acquisition of Treasury Shares through ToSTNeT-3

With respect to the acquisition of treasury shares announced yesterday (November 6, 2023), KISSEI PHARMACEUTICAL CO., LTD. (the “Company”) is announcing that it has executed the repurchases as follows.

1. Reason for the acquisition of the own shares
To execute a flexible capital policy in response to changes in the business environment, while improving capital efficiency and enhancing shareholder returns.
2. Details of the acquisition
 - 1) Type of shares acquired: Common shares of the Company
 - 2) Total number of shares acquired: 1,165,300 shares
 - 3) Total acquisition cost: 3,682,348,000 yen
 - 4) Date of the acquisition: November 7, 2023
 - 5) Acquisition method: Repurchase through ToSTNeT-3 of the Tokyo Stock Exchange
3. Status of the acquisition (from May 10, 2023 to November 7, 2023)
 - 1) Type of shares acquired: Common shares of the Company
 - 2) Total number of shares acquired: 1,479,900 shares
 - 3) Total acquisition cost: 4,632,161,800 yen
 - 4) Acquisition period: From May 10, 2023 to November 7, 2023
 - 5) Acquisition method: Market purchases on the Tokyo Stock Exchange
 1. Purchases through the Tokyo Stock Exchange Trading Network Off-Auction Own Share Repurchase Trading System (ToSTNeT-3)
 2. Market purchases based on a discretionary trading contract regarding acquisition of own shares

(Reference)

1. Details of the resolution of the Board of Directors meeting regarding acquisition of treasury shares
(Published on November 6, 2023)
 - 1) Type of shares to be acquired: Common shares of the Company
 - 2) Total number of shares to be acquired: Up to 1,200,000 shares
(Percentage of total number of issued shares (excluding treasury shares) : 2.62%)
 - 3) Total acquisition cost: 3,792,000,000 yen (maximum)
 - 4) Date of the acquisition: November 7, 2023
 - 5) Acquisition method: Repurchase through ToSTNeT-3 of the Tokyo Stock Exchange

2. Details of the resolution of the Board of Directors meeting held on May 8, 2023
 - 1) Type of shares to be acquired: Common shares of the Company
 - 2) Total number of shares to be acquired: Up to 2,000,000 shares
(Percentage of total number of issued shares (excluding treasury shares) : 4.34%)
 - 3) Total acquisition cost: 6 billion yen (maximum)
 - 4) Acquisition period: From May 10, 2023 to March 29, 2024
 - 5) Acquisition method: Market purchases on the Tokyo Stock Exchange
 1. Purchases through the Tokyo Stock Exchange Trading Network Off-Auction Own Share Repurchase Trading System (ToSTNeT-3)
 2. Market purchases based on a discretionary trading contract regarding acquisition of own shares